PDCD1 and melanoma: were found in increased abundance in responder groups of clinical trials [58,59], being positively correlated with anti-PD-1/PD-L1 treatment responses in patients with lung [60], gastrointestinal [61], and hepatocellular cancer [62] or melanoma [63].